Side Effects and Safety of Sandimmun® in Long-term Treatment of Transplant Patients
The introduction of Sandimmun® (ciclosporin) into immunosuppressive therapy has improved the results of organ transplantation with respect to patient survival, graft survival and the main post-transplant complications [5, 6, 16, 26], and the adverse reaction profile of this potent immunosuppressive agent has been established . However, long-term safety experience is still limited. To broaden knowledge in this respect, a long-term safety follow-up, primarily of bone marrow and renal transplant recipients treated with Sandimmun, has been initiated. Preliminary data of this ongoing investigation from renal transplant recipients, who provide the bulk of the information, are presented here.
KeywordsFatigue Lymphoma Corticosteroid Hydrocortisone Pancreatitis
Unable to display preview. Download preview PDF.
- 4.Borel JF (1984) Animal experiments with ciclosporin. Triangle 23: 3/4, 153Google Scholar
- 12.Kahan BD, Ried M, Newburger J (1983) Pharmacokinetics of cyclosporine in human renal transplantation. Transplant Proc 15:446–453Google Scholar
- 15.Mangal AK, Growe GH, Sinclair M et al. (1984) Acquired hemolytic anemia due to Side Effects and Safety of Sandimmun in Long-term Treatment of Transplant Patients 49 “auto”-anti-A or “auto”-anti-B induced by group 0 homograft in renal transplant recipients. Transfusion 24:201–205PubMedCrossRefGoogle Scholar
- 17.Mihatsch JM, Thiel G, Ryffel B (1985) 23. Ciclosporin-associated Nephropathy. In: Schindler R (ed) Ciclosporin in Autoimmune Diseases. 1st International Symposium, Basle, March 18–20, 1985. Springer, Berlin 24. Heidelberg New York Tokyo, p 50Google Scholar
- 18.Najarian JS, Ferguson RM, Sutherland DER et al. (1983) A prospective trial of the ef- 25. ficacy of cyclosporine in renal transplantation at the University of Minnesota. Transplant Proc 15: No. 1, 438–441Google Scholar
- 19.Oyer PE, Stinson EB, Jamieson SW et al. (1984) Cyclosporine in cardiac transplan- 26. tation: A 2Y2 year follow-up. In: B. D. Kahan, Cyclosporine, Vol. 1, Biological Activity and Clinical Applications. Grune and Stratton, Orlando, p 330–336 27.Google Scholar
- 20.Penn I (1970) Malignant tumors in organ transplant recipients. Springer, BerlinGoogle Scholar
- 21.Price CP, Deam SM, Calvin J (1983) Serum alkaline phosphatase isoenzyme in patients on cyclosporin A following renal transplantation. Clin Biochem 16, No. 5, Abstr. C314, A25Google Scholar
- 22.Reece IJ, Okereke OUJ, Painvin GA et al. (1984) Infection in cyclosporine-immunosuppressed cardiac allograft recipients. Heart Transplant 3:239–242Google Scholar
- 25.Thiel G, Harder F, Loertscher R, et al. (1983) Cyclosporin A used alone or in combination with low-dose steroids in cadaveric renal transplantation. Klin Wochenschr 61:991 —1000Google Scholar